| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
We investigated whether mesenchymal stem cells (MSCs) transplantation benefits to treatment of glioblastoma (GBM) by enhancing anti-tumor effect in combination with GSK3β inhibitors and temozolomide (TMZ). We showed that MSCs co-cultured with GBM cells participate in regulation of GBM stem-like cell (SC) morphology. We examined the interaction between patient-derived GBM-SCs and adipose tissue-derived MSCs under GSK3β inhibition and TMZ and its influence on GBM-SCs. We found that combined treatment by GSK3β inhibitor enhanced therapeutic interaction of MSCs with GBM-SCs, and that combination of low-dose AR-A014418, TMZ and MSC treatment significantly reduced cell viability and showed anti-tumor effect against patient-derived GBM-SCs. Transplantation of MSCs and GSK3β inhibition improved survival in mouse GBM model.
|
